These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36265279)

  • 1. Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents.
    Van Manh N; Hoang VH; Ngo VTH; Kang S; Jeong JJ; Ha HJ; Kim H; Kim YH; Ann J; Lee J
    Eur J Med Chem; 2022 Dec; 244():114837. PubMed ID: 36265279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design.
    Van Manh N; Hoang VH; Ngo VTH; Ann J; Jang TH; Ha JH; Song JY; Ha HJ; Kim H; Kim YH; Lee J; Lee J
    Eur J Med Chem; 2021 Dec; 226():113819. PubMed ID: 34536669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and Evaluation of Diphenyl Conjugated Imidazole Derivatives as Potential Glutaminyl Cyclase Inhibitors for Treatment of Alzheimer's Disease.
    Li M; Dong Y; Yu X; Li Y; Zou Y; Zheng Y; He Z; Liu Z; Quan J; Bu X; Wu H
    J Med Chem; 2017 Aug; 60(15):6664-6677. PubMed ID: 28700245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimer's Agents Based on Rational Design.
    Hoang VH; Tran PT; Cui M; Ngo VT; Ann J; Park J; Lee J; Choi K; Cho H; Kim H; Ha HJ; Hong HS; Choi S; Kim YH; Lee J
    J Med Chem; 2017 Mar; 60(6):2573-2590. PubMed ID: 28234463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of glutaminyl cyclase inhibitors for Alzheimer's disease.
    Coimbra JR; Sobral PJ; Santos AE; Moreira PI; Salvador JA
    Future Med Chem; 2019 Dec; 11(24):3179-3194. PubMed ID: 31838899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer's Disease.
    Feldman HH; Messer K; Qiu Y; Sabbagh M; Galasko D; Turner RS; Lopez O; Smith A; Durant J; Lupo JL; Revta C; Balasubramanian A; Kuehn-Wache K; Wassmann T; Schell-Mader S; Jacobs DM; Salmon DP; Léger G; DeMarco ML; Weber F;
    J Alzheimers Dis; 2024; 101(s1):S79-S93. PubMed ID: 39422941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human glutaminyl cyclase: Structure, function, inhibitors and involvement in Alzheimer's disease.
    Vijayan DK; Zhang KYJ
    Pharmacol Res; 2019 Sep; 147():104342. PubMed ID: 31288079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation.
    Hartlage-Rübsamen M; Bluhm A; Piechotta A; Linnert M; Rahfeld JU; Demuth HU; Lues I; Kuhn PH; Lichtenthaler SF; Roßner S; Höfling C
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29673150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer's agents: Structure-activity relationship study of Arg-mimetic region.
    Ngo VTH; Hoang VH; Tran PT; Ann J; Cui M; Park G; Choi S; Lee J; Kim H; Ha HJ; Choi K; Kim YH; Lee J
    Bioorg Med Chem; 2018 Mar; 26(5):1035-1049. PubMed ID: 29398442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.
    Morawski M; Hartlage-Rübsamen M; Jäger C; Waniek A; Schilling S; Schwab C; McGeer PL; Arendt T; Demuth HU; Rossner S
    Acta Neuropathol; 2010 Aug; 120(2):195-207. PubMed ID: 20383514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice.
    Hoffmann T; Rahfeld JU; Schenk M; Ponath F; Makioka K; Hutter-Paier B; Lues I; Lemere CA; Schilling S
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice.
    Jawhar S; Wirths O; Schilling S; Graubner S; Demuth HU; Bayer TA
    J Biol Chem; 2011 Feb; 286(6):4454-60. PubMed ID: 21148560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
    Hartlage-Rübsamen M; Morawski M; Waniek A; Jäger C; Zeitschel U; Koch B; Cynis H; Schilling S; Schliebs R; Demuth HU; Rossner S
    Acta Neuropathol; 2011 Jun; 121(6):705-19. PubMed ID: 21301857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients.
    Bridel C; Hoffmann T; Meyer A; Durieux S; Koel-Simmelink MA; Orth M; Scheltens P; Lues I; Teunissen CE
    Alzheimers Res Ther; 2017 Jun; 9(1):38. PubMed ID: 28587659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease.
    Morawski M; Schilling S; Kreuzberger M; Waniek A; Jäger C; Koch B; Cynis H; Kehlen A; Arendt T; Hartlage-Rübsamen M; Demuth HU; Roßner S
    J Alzheimers Dis; 2014; 39(2):385-400. PubMed ID: 24164736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy.
    Hoffmann T; Meyer A; Heiser U; Kurat S; Böhme L; Kleinschmidt M; Bühring KU; Hutter-Paier B; Farcher M; Demuth HU; Lues I; Schilling S
    J Pharmacol Exp Ther; 2017 Jul; 362(1):119-130. PubMed ID: 28446518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationship investigation of Phe-Arg mimetic region of human glutaminyl cyclase inhibitors.
    Ngo VTH; Hoang VH; Tran PT; Van Manh N; Ann J; Kim E; Cui M; Choi S; Lee J; Kim H; Ha HJ; Choi K; Kim YH; Lee J
    Bioorg Med Chem; 2018 Jul; 26(12):3133-3144. PubMed ID: 29705377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
    Schilling S; Zeitschel U; Hoffmann T; Heiser U; Francke M; Kehlen A; Holzer M; Hutter-Paier B; Prokesch M; Windisch M; Jagla W; Schlenzig D; Lindner C; Rudolph T; Reuter G; Cynis H; Montag D; Demuth HU; Rossner S
    Nat Med; 2008 Oct; 14(10):1106-11. PubMed ID: 18836460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The structure of the human glutaminyl cyclase-SEN177 complex indicates routes for developing new potent inhibitors as possible agents for the treatment of neurological disorders.
    Pozzi C; Di Pisa F; Benvenuti M; Mangani S
    J Biol Inorg Chem; 2018 Dec; 23(8):1219-1226. PubMed ID: 30132075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A patent review of glutaminyl cyclase inhibitors (2004-present).
    Coimbra JRM; Salvador JAR
    Expert Opin Ther Pat; 2021 Sep; 31(9):809-836. PubMed ID: 33896339
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.